Related Experiment Videos
109881 Aventis.
1Department of Chemistry, Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA. iojima@notes.cc.sunysb.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|August 7, 2003
Summary
Aventis Pharma is developing 109881, an orally and intravenously active taxoid, for taxoid-resistant solid tumors like brain and lung cancers. Clinical trials are progressing, with an oral formulation under evaluation.
Area of Science:
- Oncology
- Pharmacology
Background:
- Taxoid-resistant solid tumors present a significant therapeutic challenge.
- Development of novel taxoid-based chemotherapeutics is crucial for overcoming resistance.
Purpose of the Study:
- To evaluate the potential of 109881, an orally and intravenously active taxoid, as a treatment for taxoid-resistant solid tumors.
- To assess the safety and efficacy of 109881 in clinical trials.
Main Methods:
- Clinical trials (Phase IIa and Phase II) were conducted in the US, France, Belgium, and Germany.
- Evaluation of both oral and intravenous formulations of 109881.
Main Results:
- 109881 demonstrated activity as an orally and intravenously active taxoid.
- Ongoing clinical trials indicate continued development and evaluation of the compound.
Conclusions:
- 109881 shows promise as a potential treatment for taxoid-resistant solid tumors.
- Further investigation, including evaluation of oral formulation, is warranted.